ALK and neuroblastoma: To assess the efficacy of combined ALK and PIM inhibition in vivo, the COG-N-426 × (ALKF1245C; MYCN-WT) and COG-N-453 × (ALKF1174L; MYCN-amplified) PDX models of high-risk NB were employed.